Sustainable therapeutics & diagnostics

PRUNUS takes bold steps for the future human and animal healthcare. PRUNUS’ main platform focuses on a small molecule-based cancer immunotherapy that outperforms high-cost biologics and engineered cells.

Key concept


"Set up red flags 🚩🚩🚩 on cancer cells, the immune system will do the rest"


THE PROBLEM: 

Because sneaky cancer cells can disguise the body as self and safe, the immune system won’t attack them.

OUR SOLUTION:

Setting up foreign tags on cancer cells can help the immune system recognize and reject them as "red-flagged invaders" like bacteria and viruses. 

Technology

PRUNUS’ core technology Selective Metabolic Labeling is uniquely positioned in the field of immuno-oncology using non-toxic small molecules that can be selectively loaded into cancer cells. It takes advantage of a prodrug strategy that can selectively label proteins produced in a broad spectrum of cancer cells with foreign tags. 

This approach would serve as a powerful tool for precision therapeutics & diagnostics. Our pipeline products include small molecules, PROTACs, biologics, vaccines, and companion diagnostic tests in order to achieve maximal therapeutic potential.

About

PRUNUS Therapeutics is a Chicagoland-based biotech startup launched in 2016. The pipeline products of PRUNUS are currently under proof-of-concept studies at preclinical stage. 


まだ記事がありません。